JNJ

190.44

-0.86%↓

ABT

127.28

+0.22%↑

MDT

93.61

-0.47%↓

VEEV

294.11

+1.75%↑

A

148.33

+1.25%↑

JNJ

190.44

-0.86%↓

ABT

127.28

+0.22%↑

MDT

93.61

-0.47%↓

VEEV

294.11

+1.75%↑

A

148.33

+1.25%↑

JNJ

190.44

-0.86%↓

ABT

127.28

+0.22%↑

MDT

93.61

-0.47%↓

VEEV

294.11

+1.75%↑

A

148.33

+1.25%↑

JNJ

190.44

-0.86%↓

ABT

127.28

+0.22%↑

MDT

93.61

-0.47%↓

VEEV

294.11

+1.75%↑

A

148.33

+1.25%↑

JNJ

190.44

-0.86%↓

ABT

127.28

+0.22%↑

MDT

93.61

-0.47%↓

VEEV

294.11

+1.75%↑

A

148.33

+1.25%↑

Search

Simulations Plus Inc

Open

SectorHealthcare

17.94 2.99

Overview

Share price change

24h

Current

Min

17.15

Max

18.02

Key metrics

By Trading Economics

Income

-70M

-67M

Sales

-2.1M

20M

P/E

Sector Avg

48.528

37.461

Dividend yield

0.48

Profit margin

-330.585

Employees

243

EBITDA

-79M

-74M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-9.19% downside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.48%

2.33%

Next Earnings

29 paź 2025

Market Stats

By TradingEconomics

Market Cap

-28M

323M

Previous open

14.95

Previous close

17.94

News Sentiment

By Acuity

63%

37%

328 / 371 Ranking in Healthcare

Simulations Plus Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 paź 2025, 20:49 UTC

Earnings

Correction to Thermo Fisher Article on Oct. 22

23 paź 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 paź 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 paź 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 paź 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 paź 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 paź 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 paź 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 paź 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 paź 2025, 22:17 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 paź 2025, 21:41 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 paź 2025, 21:05 UTC

Earnings

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 paź 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

23 paź 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

23 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 paź 2025, 20:35 UTC

Earnings

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 paź 2025, 20:28 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 paź 2025, 20:15 UTC

Market Talk
Earnings

Global Commodities Roundup: Market Talk

23 paź 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Adj EPS $1.71

23 paź 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Sales $5.52B

23 paź 2025, 20:10 UTC

Earnings

Newmont Mining 3Q EPS $1.67

23 paź 2025, 20:09 UTC

Earnings

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 paź 2025, 20:07 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

23 paź 2025, 20:07 UTC

Market Talk
Earnings

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 paź 2025, 20:07 UTC

Earnings

Blackstone Looks to IPOs for Investment Exits -- Update

23 paź 2025, 20:05 UTC

Earnings

Intel 3Q Gross Margin 38.2% >INTC

23 paź 2025, 20:04 UTC

Earnings

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 paź 2025, 20:04 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 paź 2025, 20:04 UTC

Earnings

Intel: 4Q Guidance Excludes Altera >INTC

23 paź 2025, 20:04 UTC

Earnings

Intel Sees 4Q Adj EPS 8c >INTC

Peer Comparison

Price change

Simulations Plus Inc Forecast

Price Target

By TipRanks

-9.19% downside

12 Months Forecast

Average 16 USD  -9.19%

High 16 USD

Low 16 USD

Based on 3 Wall Street analysts offering 12 month price targets forSimulations Plus Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Sentiment

By Acuity

328 / 371 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat